QGel
Lausanne
About QGel
QGel’s synthetic and tunable extracellular matrix (ECM) technology mimics the complex physiology of the human body, enabling the growth of any human or animal tissue in vitro.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.0M
- Funding stage: Private Equity
- Last round: Private Equity (Dec 2016)
- Website: qgelbio.com
- Phone: +41216940707
Industries & Categories
Biotechnology, Collaboration
Social Profiles
Canonical: https://fsome.com/organization/qgel-155231 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.